Cartalax: Research Overview

Cartalax is a peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and targeted at cartilage and connective tissue. Its exact chemical description varies across sources: it is most commonly described as a tripeptide Ala-Glu-Asp (AED) derived from cartilage polypeptide fractions, though some commercial listings describe it as a tetrapeptide with an additional C-terminal residue. This guide uses the tripeptide AED description consistent with the primary published research. Cartalax has no FDA, EMA, or other Western regulatory approval.

What is Cartalax?

Cartalax is the synthetic minimal peptide analog derived from a natural cartilage polypeptide extract (Chondrolux or similar preparations). Like other Khavinson bioregulators, it is positioned as a tissue-specific gene expression modulator rather than a conventional pharmaceutical. It is presented commercially as a lyophilized powder, commonly supplied in 20 mg research vials. The compound is studied primarily in the context of chondrocyte biology, extracellular matrix maintenance, and age-related cartilage deterioration.

Proposed Mechanism

Consistent with the broader Khavinson epigenetic model, the AED sequence is proposed to bind specific DNA motifs in the minor groove of the double helix within chondrocyte nuclei, inducing partial decondensation of heterochromatin and thereby increasing transcriptional availability of genes encoding extracellular matrix components including collagen type II and proteoglycans. In vitro studies reported by the Khavinson group observed that Cartalax increased the cartilage area index in cultured explants from both young and aged donors, with greater relative effect in aged specimens. Simultaneously, the peptide was reported to increase PCNA (proliferating cell nuclear antigen) expression and reduce p53 levels in chondrocytes, creating a cellular environment associated with proliferation over apoptosis.

Research Summary

Published research on Cartalax originates from the Khavinson laboratory and affiliated Russian institutions. The available studies are primarily in vitro and animal model experiments examining chondrocyte gene expression, chromatin organization, and cartilage explant behavior. Reported findings include increased cartilage area index by 18-38% in cultured specimens, enhanced extracellular matrix synthesis markers, and modulation of cell cycle regulatory proteins. A general review of Khavinson peptide bioregulators including Cartalax is provided in the broader Advances in Gerontology series (Springer, referenced at https://link.springer.com/article/10.1134/S2079057014040134).

Research on Cartalax is concentrated in a single Russian research group; independent Western replication is limited. There are no peer-reviewed reports from independent cartilage biology laboratories, no animal studies in standard Western osteoarthritis models, and no human clinical trials. The cartilage area index data and PCNA findings, while interesting, represent early in vitro observations that cannot be treated as evidence of clinical efficacy in joint disease.

Reported Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

No validated human dose has been established. Russian-language supplement documentation and commercial sources reference subcutaneous doses of approximately 0.5-1 mg per day over 10-day courses, repeated once or twice per year. No dose-escalation, pharmacokinetic, or bioavailability data in humans have been published in the Western scientific literature.

Frequently Asked Questions

Is Cartalax a tripeptide or a tetrapeptide?

The primary published research describes the active sequence as the AED tripeptide (Ala-Glu-Asp). Commercial sources occasionally list it as a tetrapeptide with a C-terminal glycine or leucine residue. Prospective users of research-grade material should verify the sequence with the supplier and confirm against the specific literature they are referencing.

Can Cartalax treat osteoarthritis?

No clinical trial evidence supports this claim. Osteoarthritis has approved treatment guidelines based on controlled clinical data. Cartalax in vitro data suggesting chondrocyte effects does not constitute clinical evidence of efficacy in osteoarthritis. Patients with joint disease should follow established treatment pathways under physician guidance.

How does Cartalax compare to other joint peptides like BPC-157?

BPC-157 and Cartalax both lack human clinical trial evidence and are research-stage compounds. BPC-157 has a larger body of animal pharmacology from multiple independent research groups. Cartalax research is limited to a single Russian laboratory. Neither compound has regulatory approval for any clinical indication.

References

1. Khavinson VKh et al. Peptides, genome, aging. Advances in Gerontology. 2014. https://link.springer.com/article/10.1134/S2079057014040134

2. Khavinson VKh. Short peptides regulate expression of telomerase, PCNA, and p53 in cultured chondrocytes. St. Petersburg Institute of Bioregulation and Gerontology (various annual proceedings).